Cell-mediated immunity in acute nonlymphocytic leukemia: relationship to host factors, therapy, and prognosis.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000276:immunology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009578:Nitrobenzenes; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D012737:Sex Factors; D012882:Skin Tests; D014750:Vincristine / Q000627:therapeutic use
D009578:Nitrobenzenes; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin